CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments

US8946218B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Heiner Ebel · Biberach an der Riß, DE
• Sara Frattini · Castelleone, IT
• Riccardo Giovannini · Verona, IT
• Christoph Hoenke · Ingelheim am Rhein, DE
• Rocco Mazzaferro · San Giuliano Milanese, IT
• Stefan Scheuerer · Warthausen, DE

Key dates

• Filing date: May 10, 2011
• Grant date: Feb 3, 2015
• Expiry date: Sep 17, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD and pain diseases.